



Review






Cutibacterium acnes Dysbiosis: Alternative Therapeutics for Clinical Application

Sara Sá, Ruben Fernandes, Álvaro Gestoso, José Mário Macedo, Daniela Martins-Mendes,
Ana Cláudia Pereira and Pilar Baylina



Review

Cutibacterium acnes Dysbiosis: Alternative Therapeutics for Clinical Application

Sara Sá ^{1,2,3} , Ruben Fernandes ^{1,2,4} , Álvaro Gestoso ^{1,2}, José Mário Macedo ^{1,2,5} ,
Daniela Martins-Mendes ^{1,2,4} , Ana Cláudia Pereira ^{1,2,4,*}  and Pilar Baylina ^{1,2,6,*} 

- ¹ FP-BHS—Biomedical and Health Sciences Research Unit, FP-I3ID—Instituto de Investigação, Inovação e Desenvolvimento, FFP—Fundação Fernando Pessoa, 4249-004 Porto, Portugal; saravs@ufp.edu.pt (S.S.); ruben.fernandes@ufp.edu.pt (R.F.); agestoso@ufp.edu.pt (Á.G.); coelhomacedo@gmail.com (J.M.M.); danielamm@ufp.edu.pt (D.M.-M.)
- ² HE-FP—Hospital Fernando Pessoa, CECLIN—Center of Clinical Studies, 4420-096 Gondomar, Portugal
- ³ FMUP—Faculty of Medicine, University of Porto, 4420-319 Porto, Portugal
- ⁴ FCS—Faculty of Health Sciences, Fernando Pessoa University, 4220-150 Porto, Portugal
- ⁵ Faculty of Biology, Department of Functional Biology and Health Sciences, University of Vigo, 36310 Vigo, Spain
- ⁶ ESS—School of Health, IPP—Polytechnic Institute of Porto, 4200-072 Porto, Portugal
- * Correspondence: anacpereira@ufp.edu.pt (A.C.P.); pilarbaylina@ess.ipp.pt (P.B.)

Abstract: *Cutibacterium acnes* (*C. acnes*) is a Gram-positive anaerobic facultative bacterium that is part of the human skin commensal microbiome. It colonizes various regions of the body, including the face, back, and chest. While typically a harmless commensal, under certain conditions, *C. acnes* can become pathogenic, leading to or promoting conditions such as acne vulgaris (AV), post-surgical infections, prostate cancer, and sarcoidosis. Current treatments for *C. acnes* infections often involve antibiotics, but the rise of antibiotic resistance has raised concerns. This review presents the virulence factors, clinical relevance, and current treatments of *C. acnes*, highlighting its association with AV, post-surgical infections, and other diseases. It also explores alternative innovative therapies such as phage therapy in development/research that are gaining prominence, with a growing focus on personalized medical approaches. To enhance *C. acnes* treatment while minimizing side effects and antibiotic prescription concerns, numerous clinical studies have been undertaken. These investigations span various pathological profiles and employ diverse strategies, such as utilizing bacterial extracts and compounds to restore healthy skin flora. The limitations and challenges of current and innovative treatments are also addressed, emphasizing the need for multidisciplinary strategies to combat *C. acnes* infections effectively.

Keywords: *Cutibacterium acnes*; antibiotic resistance; personalized medicine; phage therapy



Citation: Sá, S.; Fernandes, R.; Gestoso, Á.; Macedo, J.M.; Martins-Mendes, D.; Pereira, A.C.; Baylina, P. *Cutibacterium acnes* Dysbiosis: Alternative Therapeutics for Clinical Application. *Appl. Sci.* **2023**, *13*, 12086. <https://doi.org/10.3390/app132112086>

Academic Editors: Gang Wei and Jongsung Lee

Received: 23 September 2023

Revised: 29 October 2023

Accepted: 1 November 2023

Published: 6 November 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

1.1. Taxonomy and Nomenclature

C. acnes was firstly described as a member of the *Bacillus* species and of the *Corynebacterium* species [1]. Ever since its first isolation, *C. acnes* has suffered multiple taxonomic reclassifications due to the technological improvements in research and diagnosis, such as proteomic and genomic analysis. In 2016, *C. acnes* was included in the *Propionibacterium* genus. However, the known genus was later divided into four genera, namely, *Propionibacterium*, *Cutibacterium*, *Acidipropionibacterium*, and *Arachnia*. *C. acnes* was included in the genus *Cutibacterium*, alongside with *Cutibacterium avidum*, *Cutibacterium granulosum*, *Cutibacterium namnetense*, and *Cutibacterium modestum* [2]. Nowadays, *C. acnes* is often described by the following subspecies: *acnes* (*C. acnes* type I), *defendens* (*C. acnes* type II), and *elongatum* (*C. acnes* type III) [2].

1.2. *C. acnes* Infection and Virulence Factors

Cutibacterium acnes, or *C. acnes*, was firstly isolated from a patient with chronic acne vulgaris (AV) in the 1900s. It constitutes a healthy human commensal, Gram-positive, and anaerobic facultative bacterium [3]. *C. acnes* has a broad distribution on the human body, including face, supra, subgingival plaque, back, chest, groin, bend of elbow, intestine, inguinal canal, forearm, palm, plantar heel, and toe, as part of the skin's microbiota [2,4]. Under normal circumstances, *C. acnes* does not cause harm and coexists peacefully with other microorganisms. In some situations, however, there can be an overgrowth that can occur when factors like excess sebum production, hormonal changes, or inflammation create conditions favorable for bacterial proliferation. This proliferation permits the formation of biofilms that allow the bacterium to adhere to surfaces, including hair follicles and sebaceous glands on the skin. These biofilms constitute one of several virulence factors that bacteria possess as part of their defense mechanism (Figure 1) [3].




Figure 1. *C. acnes* virulence factors allow the bacteria to cause an infection and to survive the host defenses. There are several mechanisms in *C. acnes* to promote the infection, the evasion of the host defenses, host tissue damage, and invasion, such as a—Lipases can break down sebum and release the free fatty acids, influencing the bacterial capacity to adhere to other cells and surfaces which leads to the formation of comedones; b—Polyunsaturated Fatty Acid Isomerase promotes the catalyzation and the isomerization of linoleic acid; c—Reactive oxygen species (ROS) produced by macrophages (c1) are reduced by *C. acnes*' radical oxygenase, inactivating its deadly effects (c2); d—Bacterial biofilms consist of an extracellular matrix composed of proteins, polysaccharides, and/or extracellular DNA. Biofilm production protects *C. acnes* against the host immune system, most likely by creating a barrier that protects the bacteria from harmful environments such as antibiotics; e—Christ-Atkins-Much-Petersen Factors (CAMP factors) produced by *C. acnes* (e1) lead to tissue damage by creating membrane pores that promote the lysis of the host cells (e2); f—Hyaluronate lyase promotes the degradation of the host

epidermis and dermis extracellular matrix components, such as glycosaminoglycans and hyaluronic acid, allowing the bacterial invasion in the host tissues by the degradation of the skin layers and dissemination of the inflammation; g—Glycosidase enzymes break carbohydrate structures such as host glycolipids and glycoproteins, which permits *C. acnes* to use host carbohydrates to grow; h—*C. acnes*' DsA1 binds to the dermatan sulfate and to fibrinogen protein, involved in the biofilm formation; j—Sialidases remove sialic acid within sialoglyco conjugates, a highly immunogenic protein, although their function in the bacteria pathogenicity is still not clear; l—Sortases F permit the attachment to different proteins, like adhesion factors. These enzymes are produced in the cytoplasm and promote the transportation of proteins to the bacterial wall.

The virulence ability comprises several molecular mechanisms that microorganisms use to infect the host cells and tissues. These virulence factors, summarized in Table 1, are associated with bacterial adhesion and tissue invasion/degradation of the host tissues, allowing the microorganism to overrun the host's immune system and antibiotic treatments [3].

Table 1. *C. acnes* virulence factors and respective function.

Virulence Factors	Function
Lipases	Enzymes involved in the metabolization of sebum and free fatty acid release and triglycerides.
Polyunsaturated Fatty Acid Isomerase	Catalyzation and isomerization of linoleic acid.
Hyaluronate Lyase	Promotes the degradation of hyaluronic acid and other glycosaminoglycans, such as chondroitin-4-sulfate, chondroitin-6-sulfate, and dermatan sulfate, of the extracellular matrix in the epidermis and dermis.
Glycosidase	Disruption of carbohydrate and glycan structures that constitute the eukaryotic host glycolipids and glycoproteins.
Sialidase	Discard the sialic acid from sialoglycoconjugates.
Radical oxygenase	Reduction of the oxygen free radicals.
Sortase F	Capacity to covalently attach to various proteins, including adhesion factors.
Porphyrin	Fluorescent molecules that can stimulate inflammatory host reactions.
Biofilm	Matrix that provides bacterial resistance to adverse compounds, such as antibiotics
Adhesin dermatan-sulfate protein	Molecular surface components that recognize adhesive molecules of the matrix.
Christie–Atkins–Munch–Petersen Factors	Promote the formation of pores in host cells membranes.

It is important to note that not all individuals carrying *C. acnes* will develop this pathogenicity. The transition from commensal to pathogenic depends on various factors, including host genetics, the local microenvironment, and the immune response. The mechanisms underlying these transitions are complex and are an active area of research in dermatology, immunology, and microbiology.

1.3. *C. acnes* Clinical Relevance

In acne, *C. acnes* can influence hair follicles, causing them to become plugged with sebum, dead skin cells, and bacteria. This creates an ideal environment for the formation of comedones (blackheads and whiteheads). Virulence factors, such as lipases and proteases, can then exacerbate inflammation and tissue damage, breaking down lipids and proteins, hence contributing to the pathogenesis of acne lesions [3]. In post-surgical infections, *C. acnes* may enter sterile tissues during surgical procedures through contaminants from the patient's skin, the air in the operating room, surgical instruments, or even the surgical team [5]. Considering that biofilms can be formed on surgical implants, tissues, or medical devices, the treatment can become a challenge, as the access to the bacteria is limited, due to the biofilm barrier, leading to bacteria proliferation and localized infections [6].

Since *C. acnes* can metabolize the lipids produced by the human’s sebaceous glands, the density of this bacterium tends to be higher in lipid-rich areas of the human body, such as the face and upper thorax [7]. This distribution is correlated with the risk of infections observed in iatrogenic procedures (post-surgical procedures in shoulders, heart, hip, and others) and to the manifestation of AV. In fact, a study performed on the University affiliated with the Hospital Network in Wisconsin identified 77 patients from post-operative cultures that tested positive for *C. acnes*: 61% were neurosurgical, 17% orthopedic, 9% cardiothoracic, 8% general surgery, and 5% from other departments [7]. The infections caused by *C. acnes* were associated with a significant morbidity in these patients and are often underestimated due to the difficulties regarding growth and detection of this bacterium in cultures [6]. Although post-surgery shoulder infections can happen due to several other microorganisms, such as *Staphylococcus aureus* and *Staphylococcus epidermidis*, studies regarding post-surgical infections, such as shoulder arthroplasty, detected *C. acnes* as the main cause in 50 to 60% of the cases [8]. Moreover, infective endocarditis, i.e., the occurrence of an infection on a heart valve and endocardial surfaces, that can lead to a systematic infection, thus raising the risk of patient mortality [9], showed that *C. acnes* has been responsible for up to 3.5% of the infection endocarditis cases [10].

Due to the capacity of *C. acnes* to modulate the inflammatory system of the host, it is also often related to sarcoidosis (SC) and prostate cancer [7].

SC is a granulomatous disorder that forms granulomas with Th1 and Th17.1 cells and constitutes a pathological condition that can affect multiple organs, often affecting the lungs and the peripheral lymph nodes. Recently, researchers mentioned the possibility of *C. acnes* infection being on the list of possible causes for the development of SC in humans, since *C. acnes* has been detected in tissues affected by SC with high frequency [11].

In prostate cancer, the inflammatory modulation has been related with prostate carcinogenesis [12]. Indeed, it has been described that the presence of *C. acnes* in patients with prostate cancer correlates to a higher infiltration of regulatory T CD4(+), FoxP3(+) cells in prostatic tissues. Scientists discovered also that this infiltration correlates to the aggressiveness of the prostatic cancer in patients positive for *C. acnes* [13].

Acne Vulgaris (AV)

AV is a multifactorial disease that affects pilosebaceous units, leading to inflammation and keratinization. AV is developed by the androgen increase in the puberty, consequent increase in the sebum production, and *C. acnes* colonization in the skin follicle [14]. This colonization leads to the activation of local inflammation and increases the host’s tissue damage [14]. Patients with AV usually begin by presenting comedones (noninflammatory lesions) that may consequently evolve to papules (inflammatory lesions), pustules, nodules, and abscesses, presenting, in severe cases, skin scars [15]. There is not a clear and unique accepted scale for rating acne. However, there are some general tools that can be useful to define or classify the severity of the observed lesions. Two of these tools are the Investigator Global Assessment of acne (IGA) (Table 2), which is accepted by the American Food and Drug Administration (FDA), and the Global Acne Grading System (GAGS) (Table 3), that also takes into consideration the location of the counted lesions [16,17].

Table 2. Investigator Global Assessment of acne (IGA) score, acne severity denomination, and type of lesions observed [17].

Score	Acne Severity Denomination	Type of Lesions Observed
0	Clear skin	No lesions observed.
1	The skin is almost unchanged	Few comedones and less, or 1, small inflammatory lesion.
2	Mild severity	12 comedones and less or equal severe inflammatory lesions.
3	Moderate severity	Many comedones and more several inflammatory lesions and less, or 1, nodule.
4	Severe severity	Many comedones and inflammatory lesions, less or equal several nodules and cysts.

Table 3. Global Acne Grading System (GAGS) scale for AV severity rating [16].

Global Score	Lesions Count
	None: 0 Mild: 1 to 18 Moderate: 31 to 38 Very severe: >39
Local score = Factor × Grade (0–4)	
Factor (1–3)	Grade (0–4)
Nose/chin: 1 Forehead/right cheek/left cheek: 2 Chest and upper back: 3	No lesions: 0 One or more comedone: 1 One or more papule: 2 One or more pustule: 3 One or more nodule: 4

Even though there are different phylotypes and subspecies of *C. acnes* in healthy skin, the phylotype IA1 is the one associated with the lesions observed in AV [18].

1.4. *C. acnes* Antibiotic Treatment

Antibiotics have been used for more than 40 years to control and promote the elimination of bacterial infections. In clinical practice, there are currently prescribed topical and oral antibiotics to control infections [19].

Topical antibiotics include clindamycin and erythromycin. These drugs work by binding to the 50s ribosomal subunit of the bacteria, disrupting protein synthesis and, ultimately, compromising cell integrity and the replication process. These antibiotics are often used in the treatment of moderate to severe acne, particularly when other topical treatments have been ineffective, and are frequently combined with other active ingredients, such as benzoyl peroxide, to improve therapeutical efficacy [20,21].

Regarding oral treatment, tetracycline antibiotics, such as doxycycline, minocycline, and tetracycline, and macrolide antibiotics, such as erythromycin, are the most commonly used. These antibiotics constitute therapeutics in cases of moderate to severe *C. acnes* infection and/or when the infection is observed in a larger area of the body. Trimethoprim-Sulfamethoxazole (TMP-SMX) is also prescribed, especially when other antibiotics are ineffective or not well tolerated [22].

However, over the last decade, *C. acnes*, much like other bacteria, has shown an increase in antibiotic resistance mechanisms, due to its overuse and/or incorrect use, with over 50% of *C. acnes* strains showing resistance to antibiotic treatments [19]. This alarming increase in bacterial survival created the necessity to search for alternative strategies with similar outcomes regarding treatment efficacy, whether by reducing antibiotic concentration or using alternative compounds. Several studies have been conducted with that goal in mind [23–27]. According to the most recent American recommendation, benzoyl peroxide (BPO) should be used as the first-line treatment for mild to moderate AV, along with a topical retinoid and/or antibiotics [23]. Moreover, other compounds have been considered (Table 4), particularly regarding their use in post-surgery infections as topical antiseptics.

Table 4. The positive and negative aspects of compounds used as antiseptics described in clinical studies for Cutibacterium acnes infections in post-surgery contexts [23–27].

Compound	Antibacterial Mechanism	Positive Factors	Negative Factors
Benzoyl peroxide (BPO)	The discharge of reactive oxygen intermediates oxidizes the proteins in the bacterial cell membrane.	No bacterial resistance to BPO has emerged despite decades of use. Keratolytic and anti-inflammatory properties are an additional component of BPO.	BPO is expensive and is a skin irritant, especially in darker skin types.

Table 4. Cont.

Compound	Antibacterial Mechanism	Positive Factors	Negative Factors
Clindamycin	Inhibits the bacterial 50S ribosome-mediated protein production.	Has a synergetic effect when used with BPO. Fox–Fordyce illness, folliculitis, periorificial face dermatitis, and rosacea have all been treated successfully with topical clindamycin, according to reports.	<i>C. acnes</i> isolates was shown to be resistant to clindamycin. Topical clindamycin side effects generally take the shape of dryness, stinging, burning, and erythema.
Micozanole Nitrate (MN)	Antifungal drug that affects the integrity of fungal cell membranes.	Annihilates <i>Malassezia furfur</i> , a fungus that provides an optimal environment for the growth of <i>C. acnes</i> .	May provoke allergic reactions, skin irritation such as erythema, pruritus, and occasionally exudation.
Hydrogen Peroxide (HP)	Is known by its powerful antiseptic activity against the vast known microorganisms in the skin. It can be used in the concentrations of 3 to 6% of (v/v). Even though the precise mechanism of action of hydrogen peroxide is unknown, it is widely thought that it is connected to its oxidizing activity.	No cases of acquired bacterial resistance to HP have been reported. PVP–I and HP interact positively.	HP concentrated solutions (20–30% or more) are extremely irritating to the skin and mucous membranes and should be handled carefully.
Chlorhexidine (CHX)	CHX has an antibacterial activity by affecting the integrity of cell membranes.	Being a highly safe topical medication, chlorhexidine is also commonly found in wound dressings and central line catheters. Chlorhexidine has a broad spectrum of activity and persistent residual effects.	Associated with poor efficacy, chlorhexidine side effects are uncommon but include minor skin irritation and, less often, allergic responses such as severe anaphylaxis.
Povidone-iodine (PVP-I)	It is hypothesized that PVP–I mechanisms include the inhibition of the electron transportation and cellular and inhibiting protein synthesis.	It is considered, among the antiseptics, the one with the broadest spectrum of activity against viruses, bacteria, molds, fungi, yeasts, and protozoa.	Low solubility, poor chemical stability, and shows local toxicity if not used in a soluble polymer matrix. PVP–I should not be used in patients with thyroid diseases and applied iodine radiotherapy and it is also contraindicated to pregnant women or during lactation, and to newborns, and to young children.
Isopropanol	It is hypothesized that alcohols promote the protein denaturation or inhibition of mRNA and protein synthesis.	Rapid bacterial activity and broad spectrum of activity (vegetative bacteria, including mycobacteria, viruses, fungi, but not against bacterial spores). No reported allergic reactions.	Alcohols' antimicrobial properties are brief, so they are commonly combined with compounds such as chlorhexidine, which keep working after the alcohol has evaporated.

2. New Therapeutic Strategies

To overcome bacterial resistance concerns, there are strategies being explored, not only envisioning therapy efficacy but also a personalized medical approach [28]. Improvements in the treatment of *C. acnes* rely on the development of novel therapies that maximize efficacy while reducing side effects, as well as issues in public health, such as antibiotics prescriptions. For that, numerous clinical studies have been conducted to understand the outcome of different treatments for *C. acnes*. Tables S1–S5 (shown in Supplementary Materials) summarize the last decade of such clinical trials associated with this strain's infection in different pathological profiles, along with summarized methodology and main outcomes in each study.

Since a healthy skin flora can be influenced by exogenous and endogenous factors causing pathological conditions for the host, one of the strategies is the use of bacterial extracts and compounds. This strategy aims to help recover the healthy state of the skin in different pathological conditions such as AV [29]. Ho et al. studied the effects of fermented postbiotics (TYCA06, AP-32 and CP-9 and collagen gel) in the growth inhibition

of *C. acnes*, as well as an in vivo assay on the skin of patients with oily skin and severe AV. The postbiotics displayed a good growth inhibition for *C. acnes*, and in clinical trials no adverse effects was observed, showing significant reduction in redness, inflammation, and accumulation of porphyrins in skin brown spots. Moreover, there was a significant improvement in the skin hydration and in the AV lesions (in only one week of treatment), even though there was no significant reduction in the sebum skin [30]. Han et al. studied the effects of the *E. faecalis* CBT SL-5 extract, isolated from healthy Korean human fecal samples in patients with mild to moderate AV. The treatment significantly reduced the phylogenetic diversity in the patient's skin and was well tolerated by the patients. However, no significant difference was observed in the treatment and in the vehicle lotion in the improvement of AV [31]. Tsai et al. applied a base cream including heat-killed *L. plantarum*-GMNL6 on one side of the face in 15 females. The treatment significantly reduced the amount of *C. acnes* and reduced, inclusively, the red areas and the porphyrin [32]. Karoglan et al. performed a microbiome transplantation of beneficial strains of *C. acnes* to the patient's skin. The results were not statistically significant but clinical improvements in the noninflammatory lesions were observed. The major limitation of the study was the absence of a control or placebo group and the small participant sample, highlighting the need for further studies with larger groups to correlate the microbiome transplantation with beneficial outcome in AV patients [33].

More recently, phage therapy has been increasingly studied as an innovative approach in bacterial infection treatments.

Phage therapy, short for bacteriophage therapy, is a type of treatment that uses bacteriophages to target and kill specific bacteria (Figure 2). Bacteriophages, often referred to as phages, are viruses that infect and replicate within bacteria, ultimately leading to the bacterial cell's death [34]. This way, phage therapy constitutes a potential approach for treating bacterial infections, including those caused by bacteria like *C. acnes*, and involves identifying and isolating specific bacteriophages that can target and infect *C. acnes* bacteria. Once suitable phages are isolated, they can be purified and used to treat the infection [35]. The phages attach to the surface of *C. acnes* bacteria, inject their genetic material, and then replicate inside the bacterial cell. This replication ultimately leads to the lysis (bursting) of the bacterial cell, killing it, and releasing more phages to attack other bacteria [35].




Figure 2. Phage isolation: phages can be collected from water center treatments, hospital facilities, lakes, and human samples. Afterwards, these phages are isolated and tested against different bacterial strains to assess the phages' antimicrobial potential in specific strains. This specificity promotes a personalized therapy, as it allows it to be applied according to the patient's specific microbiome. After proper analysis and validation, the phages of interest can be tested for different applications, such as antimicrobial drugs, drug delivery systems, and topical creams, for example.

Phage therapy entails several advantages, such as (a) specificity, as phages are highly specific to the target bacteria, reducing the risk of harming beneficial bacteria in the body; (b) reduced antibiotic resistance, since phages can be effective against bacteria with multiresistant profile and help overcome virulence mechanisms such as the production of biofilms; and (c) potential for personalized treatment, since it constitutes a therapy that can be tailored to a specific strain that is causing infection [28,34]. This therapy has been considered an optimistic possibility to provide specific treatment in infections with pathogenic bacteria and in dysbiosis conditions when compared to the use of antibiotics [28]. As such, several studies have been conducted, using phages as the vehicle to treat *C. acnes* bacterial infection.

Xuan et al. recovered isolates of *C. acnes*, among other strains, from facial abscesses of patients with severe AV. The group succeeded in the isolation of a phage, Y3Z, recovered from the sewage samples, compatible with the strains mentioned, with the ability to perform lysis in all the bacterial isolated from the lesions, showing suitable properties for phage display applications [34].

Kim et al. isolated 15 new *C. acnes* phages from patients with AV and tested them on clinical isolated strains of *C. acnes*. The results showed that very few of the pathological strains were susceptible to specific phages in the in vitro assays. However, this was a study that highlighted the benefit of using a cocktail of phages when dealing with multiple strains of pathogenic *C. acnes* [28].

In another study, Lam and the team isolated a phage from the healthy skin of volunteers that was identified as TCUCAP1. This phage could not only show an efficient lysis effect in in vitro assays with multiresistant clinical isolates of *C. acnes*, but it also demonstrated a reduction in the inflammatory lesions on mice previously injected with a multidrug-resistant clinical *C. acnes* isolate (PS023) [36]. Also using a mouse model, Rimon et al. isolated eight phages in their laboratory and *C. acnes* strains from AV subjects. The group then administered the phages topically to mice previously infected with a virulent clinical *C. acnes*. The treated mice showed a reduced histological score when compared to the nontreated mice [37].

In a phase 1 cosmetic randomized clinical trial, Golembo and the team aimed to identify and characterize phages targeting *C. acnes* in subjects with mild to moderate acne. They found broad-spectrum phages, including those targeting antibiotic-resistant strains, with safe and specific genomes. A three-phage cocktail, BX001 was employed in a topical bacteriophage. Results showed reduced *C. acnes* on the face, aligning with predictions from in silico and ex vivo assessments, suggesting the potential for topically administered phages for acne treatment [38].

An important therapeutic aspect is phages' temperate nature, allowing coexistence with their host and enabling gene transfer, including antibiotic resistance genes. The safety of phage therapy relies on understanding these dynamics. A study conducted with antibiotic treated mice was found to increase phage integration into bacterial genomes, enriching the phage metagenome with stress-specific functions, shaping the phage–bacterial network. This enrichment also included functions related to host metabolism, such as a broader carbohydrate pathway in ampicillin-treated mice [39]. Such strategies could provide a protective effect in the gut microflora during antibiotic treatments.

Despite all the advantages in this innovative approach, phage therapy also entails some challenges that make its applicability not straight forward.

Identifying and isolating appropriate phages can be challenging and time-consuming, since the affinity towards a specific strain is essential to an effective treatment. Another challenge is the regulatory approval. In many countries, phage therapy is considered experimental, failing to check all the necessary bureaucracies for clinical application and, therefore, not reaching global population. One more challenge, that somewhat correlates with the former, is the lack of clinical data. This limitation constricts the flexibility in terms of phage therapy as a personalized treatment, due to its regulatory limitations that, in the end, result in few clinical trials.

3. Conclusions

Addressing the limitations and concerns associated with current *C. acnes* treatments requires a multidisciplinary approach involving microbiology, clinical research, and regulatory frameworks. *Cutibacterium acnes* is a versatile bacterium, with both commensal and pathogenic potential, impacting various aspects of human health. Its association with conditions like acne vulgaris, post-surgical infections, and even prostate cancer underscores its clinical relevance. Current treatments, particularly antibiotic therapy, face challenges such as antibiotic resistance and side effects, among others.

Phage therapy is an area of ongoing research, and its potential for treating various bacterial infections, including those involving *C. acnes*, is being explored. Some studies have demonstrated that specific phages can effectively reduce *C. acnes* populations on the skin, potentially offering an alternative or adjunct to antibiotic treatments. However, the effectiveness may vary depending on factors such as the phage cocktail used, the patient's skin microbiome, and the specific *C. acnes* strains involved. Such specificity, while providing a challenge, can also be seen as having high potential for personalized medicine. Particularly in microbiome profiling, genetic factors, and host–pathogen interaction, understanding an individual's skin microbiome can help identify the specific strains of *C. acnes* present and their interactions with other skin bacteria. This knowledge can guide treatment decisions and the selection of targeted therapies. Genetic factors can influence how a person responds to infections and treatments. Personalized medicine may involve genetic testing to identify genetic variations that affect susceptibility to *C. acnes* infections or responses to antibiotics or other therapies. Also, understanding how an individual's immune system interacts with *C. acnes* can inform treatment strategies. Some people may have immune responses that are more effective at controlling *C. acnes*, while others may require immune-modulating therapies. Nevertheless, further research and clinical trials are needed to establish the full extent of phage therapy's effectiveness in treating *C. acnes* infections and to determine its safety and long-term outcomes. The different studies of phage therapy aim to improve treatment of pathological conditions such as AV, moving towards the decrease in the major pathogenic phylotype of *C. acnes* while preserving the skin microflora diversity. However, regulatory and clinical data limitations must be addressed for wider application in clinical context.

4. Future Perspectives

The future of *C. acnes* treatment holds promise in several areas. Microbiome manipulation represents an interesting strategy. In phage therapy, bacteriophages show potential in targeting *C. acnes* strains with specificity and reducing antibiotic resistance. Moreover, phages' potential for tailored treatments to individual patients based on their specific *C. acnes* strains and clinical profiles may improve outcomes and reduce side effects. Further research in clinical trials is needed to establish its efficacy and safety. Hence, conducting more extensive clinical studies and collecting comprehensive data on *C. acnes* infections will enhance our understanding and treatment options. Moreover, streamlining regulatory processes for innovative therapies such as phage therapy is essential to make these treatments more accessible to patients worldwide. Future developments hold the potential to revolutionize the management of *C. acnes*-related conditions, ultimately benefiting patients and public health.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/app132112086/s1>, Table S1: Brief description of the clinical trials, over the last decade, for *Cutibacterium acnes* infection in acne vulgaris (AV) treatment. Table S2: Brief description of the clinical trials, over the last decade, for *Cutibacterium acnes* infection in post-surgery shoulder infections. Table S3: Brief description of the clinical trials, over the last decade, for *Cutibacterium acnes* infection in other iatrogenic infections. Table S4: Brief description of the clinical trials, over the last decade, for *Cutibacterium acnes* infection in other skin pathologies. Table S5: Brief description of the clinical trials, over the last decade, for *Cutibacterium acnes* infection in microbiome studies. References [40–85] are cited in the Supplementary Materials.

Author Contributions: S.S.: Data research, original draft preparation; R.F.: Research, reviewing and editing; Á.G.: Research; J.M.M.: Research; D.M.-M.: Research; A.C.P.: Conceptualization, research, reviewing and editing. P.B.: Conceptualization, research, reviewing and editing. All authors have read and agreed to the published version of the manuscript.

Funding: Pilar Baylina (PB) acknowledges on the behalf of the authors the support of *Fundação para a Ciência e Tecnologia* (FCT), Portuguese Government, under the Strategic Project Reference: UID/BIM/04293/2013. PB was also supported by FEDER/02/SAICT/2020/072560.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Corvec, S.; Dagnelie, M.-A.; Khammari, A.; Dréno, B. Taxonomy and phylogeny of *Cutibacterium* (formerly *Propionibacterium*) *acnes* in inflammatory skin diseases. *Ann. Dermatol. Venereol.* **2019**, *146*, 26–30. [[CrossRef](#)] [[PubMed](#)]
2. Dekio, I.; Asahina, A.; Shah, H.N. Unravelling the eco-specificity and pathophysiological properties of *Cutibacterium* species in the light of recent taxonomic changes. *Anaerobe* **2021**, *71*, 102411. [[CrossRef](#)] [[PubMed](#)]
3. Mayslich, C.; Grange, P.A. *Cutibacterium acnes* as an Opportunistic Pathogen: An Update of Its Virulence-Associated Factors. *Microorganisms* **2021**, *9*, 303. [[CrossRef](#)] [[PubMed](#)]
4. Yang, Y.; Qu, L.; Mijakovic, I.; Wei, Y. Advances in the human skin microbiota and its roles in cutaneous diseases. *Microb. Cell Fact.* **2022**, *21*, 176. [[CrossRef](#)] [[PubMed](#)]
5. Falconer, T.M.; Baba, M.; Kruse, L.M.; Dorrestijn, O.; Donaldson, M.J.; Smith, M.M.; Figtree, M.C.; Hudson, B.J.; Cass, B.; Young, A.A. Contamination of the Surgical Field with *Propionibacterium acnes* in Primary Shoulder Arthroplasty. *J. Bone Jt. Surg. Am.* **2016**, *98*, 1722–1728. [[CrossRef](#)] [[PubMed](#)]
6. Khatoon, Z.; McTiernan, C.D.; Suuronen, E.J.; Mah, T.-F.; Alarcon, E.I. Bacterial biofilm formation on implantable devices and approaches to its treatment and prevention. *Heliyon* **2018**, *4*, e01067. [[CrossRef](#)] [[PubMed](#)]
7. Siddiqui, R.; Makhoul, Z.; Ahmed, N. The increasing importance of the gut microbiome in acne vulgaris. *Folia Microbiol.* **2022**, *67*, 825–835. [[CrossRef](#)]
8. Elston, M.J.; Dupaix, J.P.; Opanova, M.I.; Atkinson, R.E. *Cutibacterium acnes* (formerly *Propionibacterium acnes*) and Shoulder Surgery. *Hawai'i J. Health Soc. Welf.* **2019**, *78* (Suppl. S2), 3–5.
9. Martin, D.R.; Witten, J.C.; Tan, C.D.; Rodriguez, E.R.; Blackstone, E.H.; Pettersson, G.B.; Seifert, D.E.; Willard, B.B.; Apte, S.S. Proteomics identifies a convergent innate response to infective endocarditis and extensive proteolysis in vegetation components. *JCI Insight* **2020**, *5*, e135317. [[CrossRef](#)]
10. Boman, J.; Nilson, B.; Sunnerhagen, T.; Rasmussen, M. True infection or contamination in patients with positive *Cutibacterium* blood cultures—A retrospective cohort study. *Eur. J. Clin. Microbiol. Infect. Dis.* **2022**, *41*, 1029–1037. [[CrossRef](#)]
11. Kraaijvanger, R.; Veltkamp, M. The Role of *Cutibacterium acnes* in Sarcoidosis: From Antigen to Treatable Trait? *Microorganisms* **2022**, *10*, 1649. [[CrossRef](#)]
12. Ugge, H.; Carlsson, J.; Söderquist, B.; Fall, K.; Andén, O.; Davidsson, S. The influence of prostatic *Cutibacterium acnes* infection on serum levels of IL6 and CXCL8 in prostate cancer patients. *Infect. Agents Cancer* **2018**, *13*, 7. [[CrossRef](#)] [[PubMed](#)]
13. Radej, S.; Szewc, M.; Maciejewski, R. Prostate Infiltration by Treg and Th17 Cells as an Immune Response to *Propionibacterium acnes* Infection in the Course of Benign Prostatic Hyperplasia and Prostate Cancer. *Int. J. Mol. Sci.* **2022**, *23*, 8849. [[CrossRef](#)]
14. Coenye, T.; Spittaels, K.-J.; Achermann, Y. The role of biofilm formation in the pathogenesis and antimicrobial susceptibility of *Cutibacterium acnes*. *Biofilm* **2022**, *4*, 100063. [[CrossRef](#)] [[PubMed](#)]
15. Xu, H.; Li, H. Acne, the Skin Microbiome, and Antibiotic Treatment. *Am. J. Clin. Dermatol.* **2019**, *20*, 335–344. [[CrossRef](#)] [[PubMed](#)]
16. Zohra, F.T.; Sultana, T.; Islam, S.; Nasreen, A. Evaluation of Severity in Patients of Acne Vulgaris by Global Acne Grading System in Bangladesh. *Clin. Pathol. Res. J.* **2017**, *1*, 000105. [[CrossRef](#)]
17. Szymańska, A.; Budzisz, E.; Erkiert-Polgaj, A. The Anti-Acne Effect of Near-Infrared Low-Level Laser Therapy. *Clin. Cosmet. Investig. Dermatol.* **2021**, *14*, 1045–1051. [[CrossRef](#)]
18. Mawardi, P.; Ardiani, I.; Primisawitri, P.P.; Nareswari, A. Dual role of *Cutibacterium acnes* in acne vulgaris pathophysiology. *Bali Med. J.* **2021**, *10*, 486–490. [[CrossRef](#)]
19. Sheffer-Levi, S.; Rimon, A.; Lerer, V.; Shlomov, T.; Copenhagen-Glazer, S.; Rakov, C.; Zeiter, T.; Nir-Paz, R.; Hazan, R.; Molho-Pessach, V. Antibiotic Susceptibility of *Cutibacterium acnes* Strains Isolated from Israeli Acne Patients. *Acta Derm. Venereol.* **2020**, *100*, adv00295. [[CrossRef](#)]
20. Kuriyama, T.; Karasawa, T.; Williams, D.W. Chapter Thirteen—Antimicrobial Chemotherapy: Significance to Healthcare. In *Biofilms in Infection Prevention and Control*; Percival, S.L., Williams, D.W., Randle, J., Cooper, T., Eds.; Academic Press: Boston, MA, USA, 2014; pp. 209–244. [[CrossRef](#)]
21. Peckman, B.; Kharel, M.K. Erythromycin. In *Reference Module in Biomedical Sciences*; Elsevier: Amsterdam, The Netherlands, 2022. [[CrossRef](#)]
22. Alkhawaja, E.; Hammadi, S.; Abdelmalek, M.; Mahasneh, N.; Alkhawaja, B.; Abdelmalek, S.M. Antibiotic resistant *Cutibacterium acnes* among acne patients in Jordan: A cross sectional study. *BMC Dermatol.* **2020**, *20*, 17. [[CrossRef](#)]

23. Legiawati, L.; Halim, P.A.; Fitriani, M.; Hikmahrachim, H.G.; Lim, H.W. Microbiomes in Acne Vulgaris and Their Susceptibility to Antibiotics in Indonesia: A Systematic Review and Meta-Analysis. *Antibiotics* **2023**, *12*, 145. [CrossRef] [PubMed]
24. Bandyopadhyay, D. Topical Antibacterials in Dermatology. *Indian J. Dermatol.* **2021**, *66*, 117–125. [CrossRef] [PubMed]
25. Letzelter, J.; Hill, J.B.; Hacquebord, J. An Overview of Skin Antiseptics Used in Orthopaedic Surgery Procedures. *J. Am. Acad. Orthop. Surg.* **2019**, *27*, 599–606. [CrossRef] [PubMed]
26. Fatemi, F.; Najafian, J.; Savabi Nasab, S.; Nilforoushzadeh, M.A. Treatment of Acne Vulgaris Using the Combination of Topical Erythromycin and Miconazole. *J. Ski. Stem Cell* **2014**, *1*, e23330. [CrossRef]
27. National Center for Biotechnology Information. PubChem Compound Summary for CID 68553, Miconazole Nitrate. 2023. Available online: <https://pubchem.ncbi.nlm.nih.gov/compound/Miconazole-nitrate> (accessed on 18 September 2023).
28. Kim, S.; Song, H.; Jin, J.S.; Lee, W.J.; Kim, J. Genomic and Phenotypic Characterization of *Cutibacterium acnes* Bacteriophages Isolated from Acne Patients. *Antibiotics* **2022**, *11*, 1041. [CrossRef]
29. Condrò, G.; Guerini, M.; Castello, M.; Perugini, P. Acne Vulgaris, Atopic Dermatitis and Rosacea: The Role of the Skin Microbiota—A Review. *Biomedicines* **2022**, *10*, 2523. [CrossRef]
30. Ho, H.-H.; Chen, C.-W.; Yi, T.-H.; Huang, Y.-F.; Kuo, Y.-W.; Lin, J.-H.; Chen, J.-F.; Tsai, S.-Y.; Chan, L.-P.; Liang, C.-H. Novel application of a Co-Fermented postbiotics of TYCA06/AP-32/CP-9/collagen in the improvement of acne vulgaris—A randomized clinical study of efficacy evaluation. *J. Cosmet. Dermatol.* **2022**, *21*, 6249–6260. [CrossRef]
31. Han, H.S.; Shin, S.H.; Choi, B.-Y.; Koo, N.; Lim, S.; Son, D.; Chung, M.J.; Park, K.Y.; Sul, W.J. A split face study on the effect of an anti-acne product containing fermentation products of *Enterococcus faecalis* CBT SL-5 on skin microbiome modification and acne improvement. *J. Microbiol.* **2022**, *60*, 488–495. [CrossRef]
32. Tsai, W.; Chou, C.; Chiang, Y.; Lin, C.; Lee, C. Regulatory effects of *Lactobacillus plantarum*-GMNL6 on human skin health by improving skin microbiome. *Int. J. Med. Sci.* **2021**, *18*, 1114–1120. [CrossRef]
33. Karoglan, A.; Paetzold, B.; Pereira de Lima, J.; Brüggemann, H.; Tüting, T.; Schanze, D.; Güell, M.; Gollnick, H. Safety and Efficacy of Topically Applied Selected *Cutibacterium acnes* Strains over Five Weeks in Patients with Acne Vulgaris: An Open-label, Pilot Study. *Acta Derm. Venereol.* **2019**, *99*, 1253–1257. [CrossRef]
34. Xuan, G.; Wang, Y.; Wang, Y.; Lin, H.; Wang, C.; Wang, J. Characterization of the newly isolated phage Y3Z against multi-drug resistant *Cutibacterium acnes*. *Microb. Pathog.* **2023**, *180*, 106111. [CrossRef]
35. Han, M.-H.; Khan, S.A.; Moon, G.-S. *Cutibacterium acnes* KCTC 3314 Growth Reduction with the Combined Use of Bacteriophage PAP 1-1 and Nisin. *Antibiotics* **2023**, *12*, 1035. [CrossRef]
36. Lam, H.Y.P.; Lai, M.-J.; Chen, T.-Y.; Wu, W.-J.; Peng, S.-Y.; Chang, K.-C. Therapeutic Effect of a Newly Isolated Lytic Bacteriophage against Multi-Drug-Resistant *Cutibacterium acnes* Infection in Mice. *Int. J. Mol. Sci.* **2021**, *22*, 7031. [CrossRef] [PubMed]
37. Rimon, A.; Rakov, C.; Lerer, V.; Sheffer-Levi, S.; Oren, S.A.; Shlomov, T.; Shasha, L.; Lubin, R.; Zubeidat, K.; Jaber, N.; et al. Topical phage therapy in a mouse model of *Cutibacterium acnes*-induced acne-like lesions. *Nat. Commun.* **2023**, *14*, 1005. [CrossRef] [PubMed]
38. Golembo, M.; Puttagunta, S.; Rappo, U.; Weinstock, E.; Engelstein, R.; Gahali-Sass, I.; Moses, A.; Kario, E.; Ben-Dor Cohen, E.; Nicenboim, J.; et al. Development of a topical bacteriophage gel targeting *Cutibacterium acnes* for acne prone skin and results of a phase 1 cosmetic randomized clinical trial. *Ski. Health Dis.* **2022**, *2*, e93. [CrossRef] [PubMed]
39. Modi, S.R.; Lee, H.H.; Spina, C.S.; Collins, J.J. Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome. *Nature* **2013**, *499*, 219–222. [CrossRef] [PubMed]
40. Nitayavardhana, S.; Manuskiatti, W.; Cembrano, K.A.G.; Wanitphadeedecha, R. A Comparative Study Between Once-Weekly and Alternating Twice-Weekly Regimen Using Blue (470 nm) and Red (640 nm) Light Combination LED Phototherapy for Moderate-to-Severe Acne Vulgaris. *Lasers Surg. Med.* **2021**, *53*, 1080–1085. [CrossRef]
41. Jain, S.; Yadav, V.; Bhatia, N. Clinical Pharmacokinetics, Safety and Exploratory Efficacy Study of a Topical Bactericidal VB-1953: Analysis of Single and Multiple Doses in a Phase I Trial in Acne Vulgaris Subjects. *Clin. Drug Investig.* **2020**, *40*, 259–268. [CrossRef]
42. Chottawornsak, N.; Chongpison, Y.; Asawanonda, P. Topical 2% ketoconazole cream monotherapy significantly improves adult female acne: A double-blind, randomized. *J. Dermatol.* **2019**, *46*, 1184–1189. [CrossRef]
43. Nawarathne, N.W.; Wijesekera, K.; Mudiyansele, W.; Gaya, D.; Wijayarathne, B.; Napagoda, M. Development of Novel Topical Cosmeceutical Formulations from *Nigella sativa* L. with Antimicrobial Activity against Acne-Causing Microorganisms. *Sci. World J.* **2019**, *2019*, 5985207. [CrossRef]
44. Weber, N.; Schwabe, K.; Schempp, C.M. Effect of a botanical cleansing lotion on skin sebum and erythema of the face: A randomized controlled blinded half-side comparison. *J. Cosmet. Dermatol.* **2018**, *18*, 821–826. [CrossRef] [PubMed]
45. Hou, J.H.; Park, C.K.; Koo, B.; Lee, K.Y. Anti-acne properties of hydrophobic fraction of red ginseng (*Panax ginseng* C.A. Meyer) and its active components. *Phyther. Res.* **2018**, *33*, 584–590. [CrossRef] [PubMed]
46. Choi, S.; Seo, J.; Kim, K. Comparative study of the bactericidal effects of indocyanine green-and methyl aminolevulinate-based photodynamic therapy on *Propionibacterium acnes* as a new treatment for acne. *J. Dermatol.* **2018**, *45*, 824–829. [CrossRef] [PubMed]
47. Kim, M.; Kerrouche, N. Combination of benzoyl peroxide 5% gel with liquid cleanser and moisturizer SPF 30 in acne treatment results in high levels of subject satisfaction, good adherence and favorable tolerability. *J. Dermatolog. Treat.* **2018**, *29*, 49–54. [CrossRef] [PubMed]

48. Dreno, B.; Martin, R.; Moyal, D.; Henley, J.B.; Khammari, A.; Seité, S. Skin microbiome and acne vulgaris: Staphylococcus, a new actor in acne. *Exp. Dermatol.* **2017**, *26*, 798–803. [[CrossRef](#)]
49. Kawashima, M.; Nagare, T.; Katsuramaki, T. Open-label, randomized, multicenter, phase III study to evaluate the safety and efficacy of benzoyl peroxide gel in long-term use in patients with acne vulgaris: A secondary publication. *J. Dermatol.* **2017**, *44*, 635–643. [[CrossRef](#)]
50. Richter, C.; Trojahn, C.; Dobos, G.; Kottner, J. Follicular fluorescence quantity to characterize acne severity: A validation study. *Ski. Res. Technol.* **2016**, *22*, 451–459. [[CrossRef](#)]
51. Ma, Y.; Chen, Q.; Liu, Y.; Wang, Q.; Huang, Z.; Xiang, L. Photodiagnosis and Photodynamic Therapy Effects of 5-aminolevulinic acid photodynamic therapy on TLRs in acne lesions and keratinocytes co-cultured with *P. acnes*. *Photodiagnosis Photodyn. Ther.* **2016**, *15*, 172–181. [[CrossRef](#)]
52. Hassan, N.; Shady, M.; Ibrahim, M. Intense pulsed light versus photodynamic therapy using liposomal methylene blue gel for the treatment of truncal acne vulgaris: A comparative randomized split body study. *Arch. Dermatol. Res.* **2016**, *308*, 263–268. [[CrossRef](#)]
53. Pan-in, P.; Wongsomboon, A.; Kokpol, C. Depositing a-mangostin nanoparticles to sebaceous gland area for acne treatment. *J. Pharmacol. Sci.* **2015**, *129*, 226–232. [[CrossRef](#)]
54. Pezza, M.; Carlomagno, V. Inositol in women suffering from acne and PCOS: A randomized study. *Glob. Dermatol.* **2017**, *4*, 1–4. [[CrossRef](#)]
55. Han, S.M.; Lee, K.G.; Pak, S.C. Effects of cosmetics containing purified honeybee (*Apis mellifera* L.) venom on acne vulgaris. *J. Integr. Med.* **2013**, *11*, 320–326. [[CrossRef](#)] [[PubMed](#)]
56. Takigawa, M.; Tokura, Y.; Shimada, S.; Furukawa, F.; Noguchi, N.; Ito, T. Clinical and bacteriological evaluation of adapalene 0.1% gel plus nadifloxacin 1% cream versus adapalene 0.1% gel in patients with acne vulgaris. *J. Dermatol.* **2013**, *40*, 620–625. [[CrossRef](#)] [[PubMed](#)]
57. Symonds, T.; Grant, A.; Doma, K.; Hinton, D.; Wilkinson, M.; Morse, L. The efficacy of topical preparations in reducing the incidence of *Cutibacterium acnes* at the start and conclusion of total shoulder arthroplasty: A randomized controlled trial. *J. Shoulder Elb. Surg.* **2022**, *31*, 1115–1121. [[CrossRef](#)] [[PubMed](#)]
58. Unterfrauner, I.; Phm, M.B.A.; Wieser, K.; Catanzaro, S.; Bouaicha, S. Acne cream reduces the deep *Cutibacterium acnes* tissue load before elective open shoulder surgery: A randomized controlled pilot trial. *J. Shoulder Elb. Surg. Board. Trust.* **2022**, *31*, 897–905. [[CrossRef](#)]
59. Cotter, E.J.; Cotter, L.M.; Franczek, E.B.; Godfrey, J.J.; Hetzel, S.J.; Safdar, N.; Dai, T.; Arkin, L.; Grogan, B.F. Efficacy of combinational therapy using blue light and benzoyl peroxide in reducing *Cutibacterium acnes* bioburden at the deltopectoral interval: A randomized controlled trial. *J. Shoulder Elb. Surg.* **2021**, *30*, 2671–2681. [[CrossRef](#)]
60. Grewal, G.; Polisetty, T.; Boltuch, A.; Colley, R.; Tapia, R.; Levy, J.C. Does application of hydrogen peroxide to the dermis reduce incidence of *Cutibacterium acnes* during shoulder arthroplasty: A randomized controlled trial. *J. Shoulder Elb. Surg.* **2021**, *30*, 1827–1833. [[CrossRef](#)]
61. Steffen, V.; Moor, B.K.; Bertrand, L.; Troillet, N.; Emonet, S.; Gallusser, N. Subcutaneous tissue disinfection significantly reduces *Cutibacterium acnes* burden in primary open shoulder surgery. *J. Shoulder Elb. Surg. Board. Trust.* **2021**, *30*, 1537–1543. [[CrossRef](#)]
62. Scheer, J.H.; Serrander, L.; Kal, A. Benzoyl peroxide treatment decreases *Cutibacterium acnes* in shoulder surgery, from skin incision until wound closure. *J. Shoulder Elb. Surg. Board. Trust.* **2021**, *30*, 1316–1323. [[CrossRef](#)]
63. Dörfel, D.; Maiwald, M.; Daeschlein, G.; Müller, G.; Hudek, R.; Assadian, O.; Kampf, G.; Kohlmann, T.; Harnoss, J.C.; Kramer, A. Comparison of the antimicrobial efficacy of povidone-iodine-alcohol versus chlorhexidine-alcohol for surgical skin preparation on the aerobic and anaerobic skin flora of the shoulder region. *Antimicrob. Resist. Infect. Control.* **2021**, *10*, 17. [[CrossRef](#)]
64. Hsu, J.E.; Whitson, A.J.; Woodhead, B.M.; Napierala, M.A.; Gong, D.; Iii, F.A.M. Randomized controlled trial of chlorhexidine wash versus benzoyl peroxide soap for home surgical preparation: Neither is effective in removing *Cutibacterium* from the skin of shoulder arthroplasty patients. *Int. Orthop.* **2020**, *44*, 1325–1329. [[CrossRef](#)] [[PubMed](#)]
65. Van Diek, F.M.; Pruijn, N.; Spijkers, K.M.; Mulder, B.; Kosse, N.M.; Dorrestijn, O. The presence of *Cutibacterium acnes* on the skin of the shoulder after the use of benzoyl peroxide: A placebo-controlled, double-blinded, randomized trial. *J. Shoulder Elb. Surg.* **2020**, *29*, 768–774. [[CrossRef](#)] [[PubMed](#)]
66. Stull, J.D.; Nicholson, T.A.; Davis, D.E.; Namdari, S. Addition of 3% hydrogen peroxide to standard skin preparation reduces *Cutibacterium acnes*—positive culture rate in shoulder surgery: A prospective randomized controlled trial. *J. Shoulder Elb. Surg.* **2019**, *29*, 212–216. [[CrossRef](#)] [[PubMed](#)]
67. Chalmers, P.N.; Beck, L.; Stertz, I.; Tashjian, R.Z. Hydrogen peroxide skin preparation reduces *Cutibacterium acnes* in shoulder arthroplasty: A prospective, blinded, controlled trial. *J. Shoulder Elb. Surg.* **2019**, *28*, 1554–1561. [[CrossRef](#)] [[PubMed](#)]
68. Hancock, D.S.; Rupasinghe, S.L.; Elkinson, I.; Bloom, M.G.; Larsen, P.D. Benzoyl peroxide+chlorhexidine versus chlorhexidine alone skin preparation to reduce *Propionibacterium acnes*: A randomized controlled trial. *ANZ J. Surg.* **2018**, *88*, 1182–1186. [[CrossRef](#)]
69. Smith, M.L.; Gotmaker, R.; Hoy, G.A.; Ek, E.T.; Carr, A.; Flynn, J.N.; Evans, M.C. Minimizing *Propionibacterium acnes* contamination in shoulder arthroplasty: Use of a wound protector. *ANZ J. Surg.* **2018**, *88*, 1178–1181. [[CrossRef](#)]
70. Blonna, D.; Allizond, V.; Bellato, E.; Banche, G.; Cuffini, A.M.; Castoldi, F.; Rossi, R. Single versus Double Skin Preparation for Infection Prevention in Proximal Humeral Fracture Surgery. *Biomed. Res. Int.* **2018**, *2018*, 7. [[CrossRef](#)]

71. Kolakowski, L.; Lai, J.K.; Duvall, G.T.; Jauregui, J.J.; Dubina, A.G.; Jones, D.L.; Williams, K.M.; Hasan, S.A.; Iii, R.F.H.; Gilotra, M.N. Neer Award 2018: Benzoyl peroxide effectively decreases preoperative *Cutibacterium acnes* shoulder burden: A prospective randomized controlled trial. *J. Shoulder Elb. Surg.* **2018**, *27*, 1539–1544. [[CrossRef](#)]
72. Patzer, T.; Petersdorf, S.; Krauspe, R.; Verde, P.E.; Henrich, B.; Hufeland, M. Prevalence of *Propionibacterium acnes* in the glenohumeral compared with the subacromial space in primary shoulder arthroscopies. *J. Shoulder Elb. Surg. Board. Trust.* **2017**, *27*, 771–776. [[CrossRef](#)]
73. Yamakado, K. *Propionibacterium acnes* Suture Contamination in Arthroscopic Rotator Cuff Repair: A Prospective Randomized Study. *Arthrosc. J. Arthrosc. Relat. Surg.* **2017**, *34*, 1151–1155. [[CrossRef](#)]
74. Dizay, H.H.; Lau, D.G.; Nottage, W.M. Benzoyl peroxide and clindamycin topical skin preparation decreases *Propionibacterium acnes* colonization in shoulder arthroscopy. *J. Shoulder Elb. Surg.* **2017**, *26*, 1190–1195. [[CrossRef](#)] [[PubMed](#)]
75. Johansson, L.; Hailer, N.P.; Rahme, H. High incidence of periprosthetic joint infection with *propionibacterium acnes* after the use of a stemless shoulder prosthesis with metaphyseal screw fixation—A retrospective cohort study of 241 patients *propionibacter* infections after eclipse TSA. *BMC Musculoskelet. Disord.* **2017**, *18*, 203. [[CrossRef](#)]
76. Marecek, G.S.; Weatherford, B.M.; Fuller, E.B.; Saltzman, M.D. The effect of axillary hair on surgical antisepsis around the shoulder. *J. Shoulder Elb. Surg.* **2014**, *24*, 804–808. [[CrossRef](#)] [[PubMed](#)]
77. Gomes, A.; Van Oosten, M.; Bijker, K.L.B.; Boiten, K.E.; Salomon, E.N.; Rosema, S.; Rossen, J.W.A.; Natour, E.; Douglas, Y.L.; Kampinga, G.A.; et al. Sonication of heart valves detects more bacteria in infective endocarditis. *Sci. Rep.* **2018**, *8*, 12967. [[CrossRef](#)]
78. Ploeger, M.M.; Jacobs, C.; Gathen, M.; Kaup, E.; Randau, T.M.; Friedrich, M.J.; Hischebeth, G.T.; Wimmer, M.D. Fluid collection bags pose a threat for bacterial contamination in primary total hip arthroplasty: A prospective, internally controlled, non-blinded trial. *Arch. Orthop. Trauma. Surg.* **2018**, *138*, 1159–1163. [[CrossRef](#)]
79. Machado, I.; Baptista, D.C.; Canato, F.; Giacomelli, G.; Eduardo, C.; Falchete, R.; Carneiro, M. Colonization of oropharynx and lower respiratory tract in critical patients: Risk of ventilator-associated pneumonia. *Arch. Oral. Biol.* **2018**, *85*, 64–69. [[CrossRef](#)]
80. Litrico, S.; Recanati, G.; Gennari, A.; Maillot, C.; Saffarini, M.; Le Huec, J.C. Single-use instrumentation in posterior lumbar fusion could decrease incidence of surgical site infection: A prospective bi-centric study. *Eur. J. Orthop. Surg. Traumatol.* **2016**, *26*, 21–26. [[CrossRef](#)]
81. Falk-Brynhildsen, K.; Söderquist, B.; Friberg, Ö.; Nilsson, U.G. Bacterial recolonization of the skin and wound contamination during cardiac surgery: A randomized controlled trial of the use of plastic adhesive drape compared with bare skin. *J. Hosp. Infect.* **2013**, *84*, 151–158. [[CrossRef](#)]
82. Rieger, U.M.; Mesina, J.; Kalbermatten, D.F.; Haug, M.; Frey, H.P.; Pico, R.; Frei, R.; Pierer, G.; Lüscher, N.J.; Trampuz, A. Bacterial biofilms and capsular contracture in patients with breast implants. *Br. J. Surg.* **2013**, *100*, 768–774. [[CrossRef](#)]
83. Craig, J.P.; Cruzat, A.; Cheung, I.M.Y.; Watters, G.A.; Wang, M.T.M. Randomized masked trial of the clinical efficacy of MGO Manuka Honey microemulsion eye cream for the treatment of blepharitis. *Ocul. Surf.* **2020**, *18*, 170–177. [[CrossRef](#)]
84. Saxena, R.; Mittal, P.; Clavaud, C.; Dhakan, D.B.; Roy, N.; Breton, L.; Misra, N.; Sharma, V.K. Longitudinal study of the scalp microbiome suggests coconut oil to enrich healthy scalp commensals. *Sci. Rep.* **2021**, *11*, 7220. [[CrossRef](#)] [[PubMed](#)]
85. Ramakrishnan, V.R.; Feazel, L.M.; Gitomer, S.A.; Ir, D.; Robertson, C.E.; Daniel, N. The Microbiome of the Middle Meatus in Healthy Adults. *PLoS ONE* **2013**, *8*, e85507. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.